Non-Pressurized Topical Spray of Diclofenac Diethylamine by Pawar, Neelam & Chaudhary, Hema
 Research Article 
 
Non-Pressurized Topical Spray of Diclofenac Diethylamine 
 
Neelam Pawar
*
 and Hema Chaudhary 
 
P. D. Memorial College of Pharmacy, Sector-3A; Sarai Aurangabad, Bahadurgarh, India 
 
 
*Correspondence Info: 
Neelam Pawar,  
P. D. Memorial College of Pharmacy, 
Sector-3A; Sarai Aurangabad, 
Bahadurgarh, India 
Email: neelampawar5555@gmail.com   
 
Keywords:  
DDEA,  
Non-pressurized topical spray,  
Metering chamber,  
Drug release,  
Kinetics,  
Stability 
 
 
 
1. Introduction 
Non pressurized topical spray does not contain any propellant so more user friendly, environmentally acceptable, 
by pass GIT tract to prevent GI irritation, cut down cost of formulation gives topical action, maximum amount of drug 
reaches to the site of action, maximum absorption of drug, ease of application and increase patient compliance. The 
ultimate goal of non pressurized topical delivery system to site specific delivery of drug to ensure the absorption through 
skin deferent methodologies have been investigated including use of drug derivatives, vehicle, film formers, solubilizer, 
permeation enhancer, plasticiser and buffering agent[1]. A non-steroidal anti-inflammatory drug i.e. Diclofenac 
Diethylamine (DDEA) with N-ethyl ethanamine (1:1) has allied selective inhibition of COX-2 enzyme(precursor of 
prostaglandins) which contribute a significant role in the pathogenesis of pain, inflammation, fever and inhibits production 
of proteogly can in cartilage. The solubility of DDEA (Class II BCS drug) is depends on the pH of the surrounding solution 
and it undergoes an intermolecular cyclization in the acidic condition, which can cause its inactivation [2]. DDEA possesses 
other characteristics such as poor bioavailability (40-60%), short biological half life (2-3), high permeability are the 
foremost contemplation in release studies of pharmaceutical active candidate[3]. 
The non pressurized spraying dosage form can be solution/suspension in which the therapeutic agent and a choice 
of excipients are dissolved in the selected solvent system which are then filled in the spraying bottles [4]. Solution delivers 
the drug to the surface of the skin; drug is distributed by placing the device gently against the skin and triggering, causing it 
to discharge a light spray containing a proprietary formulation of the drug on the skin, the drug is then absorbed [5]. 
The key idea in non pressurized spray dispensing system, spray pump operate on the mechanical energy provide 
by depression of actuator, while aerosol valves operate on the energy provided by propellant in the system.  The potential of 
HDPE bottle for packing of non pressurized spray are tremendous with shipment at reduced weight, immune from denting 
and breakage, less expensive handling, no possibilities of corrosiveness, proper labelling, application aided by improved 
adhesive and strechability of labels. The versatility of container includes metering valves for delivering specific quantities 
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of product at each discharge to avoid wastage of formulation [6]. The actuators are available in different style depending 
upon the use like dental, dermal, through and oral with foldable and unfold able arms. The spray pump operates on 
mechanical energy provided by depression of actuator. The metering chamber communicates with composition by means of 
dip tube. By using metered dose pump it is possible to deliver precise amount of film on to skin and this in association with 
knowledge of concentration of physiologically active ingredient within the composition can serve to ensure that level of 
active ingredient tightly controlled. When actuating the pump, a piston moves descending in the metering chamber, prevent 
backflow into dip tube, generate pressure which force air previous to priming or liquid outward through actuator. When the 
actuation pressure is takes away, a spring will force the piston to go back to its initial position. This makes a vacuum in the 
metering chamber which pulls the liquid form the container by lifting up the ball from the ball seal over the dip tube at the 
underside of metering chamber [7]. 
 
Fig. A: Spray valve component (actuator, valve, stem, gaskets, mounting cups, valve spring) 
 
2. Materials and Method 
The study sample consisted of chemicals and reagents: DDEA was obtained from Arti Drugs Ltd., India; ethanol 
(Hayman Ltd., England), isopropyl alcohol(Deepak Corporation Ltd., India), propylene glycol (Changshu Yangua Chemical 
Co. Ltd., China), menthol (Nector Life Science Ltd., India), Plasdone K-90(ISP Pharmaceutical, USA), isopropyl myristate 
(Finar Chemical Ltd. India), Citric acid(Canton Lab Pvt. Ltd., India), Soya lecithin(Shree Nidhioils & food Pvt. Ltd., India) 
were used. Dialysis membrane (M. weight cut-off 12,000 Da) was obtained from Himedia Labs, India. 
2.1 Selection of containers, spray pumps and actuators 
Specially designed HDPE bottle, Screw type (Medsize, USA) were utilized for filling topical spray formulations. 
Pump (VP6/9018/415+) (Aptar Pharma Pvt. Ltd., India) were procured for nonpressurized spray delivery system based on 
physic-chemical compatibility of components with formulation. 200 mcl pump volume selected based on required dose of 
drug. Actuator (PR139.A01.RS3.L.TM) with actuating volume of 200 mcl was selected and used. 
2.2 Non Pressurized Spray Formulation and Development 
The spray developed as topical solution made up of non aqueous vehicle, plasticizer, permeation enhancer, 
buffering agent, emollient, film former, cooling agent. DDEA was dissolved in ethanol in a separate vessel until clear 
solution was obtained. The polymeric system was prepared by incorporating isopropyl alcohol and PVP into solvent 
system. With continuous stirring lecithin, propylene glycol, peppermint oil and isopropyl myristate was added to the 
mixture. (Table A). The pH was adjusted by adding citric acid into spray system. Volume of final solution was made up by 
ethanol in such a way that desired amount of drug could be obtained after each actuation, solution was stirred and pH was 
observed. 
2.3 Characterization 
The formulation was observed for organoleptic (color, physical state, odour& nature) and IR spectra of the 
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formulation recorded by scanning in wavelength region of 650-4000 cm
-1
 in a FTIR-Spectrophotometer (Jasco FT-761, FT-
IR spectrophotometer). The amount of spray is transferred into a stopper volumetric flask (250ml) and was shaken with 
methanol (50ml) to extract the drug and filtered. The filtrate volume was made up to with methanol (50ml), pipette out 
(0.5ml) and its volume was made up to with methanol (25ml) [8]. 
2.3.1 Pump Delivery / Shot Weight
 
 After dismissal one shot into air;  one unit weighted and process repeated for ten times to determined the average 
weight delivery per shot[individual weight (divergence should be less than 6%, should not  more than 10%from the average 
weight for passing pump delivery)[9]. 
2.3.2 Evaporation Time and Weight Checking  
The time needed for spray film to dry estimated by spraying the formulation on to ethanol sensitive paper and 
drying time was reported; the weight was done by periodically adding un-filled spray container to filling lines which after 
filling with concentrated are moved and reweighted [10]. 
Table A: Parameter Summarization of Spray Formulation (%W/W) 
Batch 
Codes 
Quantitative Composition 
Drug IPA Ethanol IPM Peppermint oil Menthol  Citric acid PK Lecithin PG 
F1 4.64 45.86  qs -  - - -  - -  -  
F2 4.64 36.66  qs 10.00  - -  -   -  - -  
F3 4.64 31.36  qs 15.00 -  - -  - -   - 
F4 4.64 26.36  qs 20.00  - -   - -  -   - 
F5 4.64 31.16  qs 15.00 0.20 -  - - -  -  
F6 4.64 30.96  qs 15.00 0.40  - -  -   -  - 
F7 4.64 29.96  qs 15.00 1.40 - -  -  -  - 
F8 4.64 29.16  qs 15.00 0.20 2.00  - -  -  -  
F9 4.64 27.16  qs 15.00 0.20 4.00  - -  - -  
F10 4.64 25.16 qs 15.00 0.20 6.00 -  -  -  -  
F11  4.64 30.36 qs 15.00 0.20 -  0.80  -  -  -  
F12  4.64 30.16  qs 15.00 0.20 -  1.00  -  -  -  
F13  4.64 29.96  qs 15.00 0.20 -  1.20  -  -  -  
F14 4.64 29.66  qs 15.00 0.20 - 1.50 - -  -  
F15 4.64 29.36  qs 15.00 0.20  - 1.80 -  -   - 
F16 4.64 29.16  qs 15.00 0.20 - 2.00 -  -  - 
F17  4.64 qs -  49.16  0.20 -  1.00  -  -  -  
F18  4.64 -  qs 45.16  0.20 -  1.00  -  -   
F19 4.64 - qs 44.91  0.20 - 1.00  0.25 -   - 
F20 4.64  - qs 44.76  0.20  - 1.00  0.40 -  -  
F21 4.64 - qs 44.71  0.20 - 1.00  0.60 -  -  
F22  4.64 -  qs 40.91  0.20 -  1.00  0.25  4.00   
F23  4.64 -  qs 30.91  0.20 -  1.00  0.25  4.00  10.00  
F24 4.64  - qs 44.51  0.20 -  1.00  0.25 0.20 5.00  
F25 4.64 - qs 44.31  0.20 - 1.00  0.25 0.40 7.50  
F26 4.64  - qs 44.11  0.20 -  1.00  0.25 0.60 10.00  
F27 4.64 - qs 38.71 0.20 - 1.00  0.25 0.20 15.00 
F28 4.64  - qs 36.21 0.20 -  1.00  0.25 0.20 20.00 
F29 4.64  - qs 33.71  0.20 -  1.00  0.25 0.20 25.00 
F30  4.64 -  qs 29.71 0.20 -  1.00 0.25 0.20 15.00 
IPA=Isopropyl Alcohol; IPM= Isopropyl Myristate; PG=Propylene Glycol; PK= Plasdone K-90 
 For weight examination, a spray was fired into beaker, for extraction of diclofenac done with the help of methanol. 
This solution was further diluted with methanol (10ml). From this solution (1ml) was taken and diluted with methanol 
(10ml). Drug content was analyzed by UV-Visible spectrophotometer (Jasco-UV spectrophotometer)
 
[11]. 
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2.3.3 Delivered Dose Uniformity (Content Uniformity)
 
Metered-dose topical sprays containing solution within an apparatus able of quantitatively holding the dose leaving 
from actuator of the atomizing device. Shake the container (5sec) and discharge once to waste. Then, wait (5sec), shake 
(5sec), discharge again to waste and repeat this process for three actuations. After 2sec, fire one dose of the metered-dose 
topical spray into the collecting container by actuating the atomizing device &collect the contents of the collecting 
container by successive rinses. The content of drug in the collective rinses determine by evaluated the content uniformity at 
6
th
, 7
th
, 8
th
, 82
th
, 83
th
, 84
th
, 164
th
, 165
th
, and 166
th
 shots[12]. 
2.3.4 Skin Permeation Studies 
The amount of permeation (application of fixed dose mimics) that would be in practical actual quantity of topical 
spray was actuated on the top of synthetic membrane with the help of 200mcl pump (0.5625g of formulation was applied 
on the surface area of 1.76 cm
2
 of membrane) [13]. The receptor phase was phosphate buffer (pH 6.78) prepared by 
dissolved sodium hydroxide in water to produce a solution (40-60% w/v) &diluted with sodium hydroxide (8g in 1000ml) 
thermostated at 37 C and stirred with a Teflon coated magnetic stirrer. Cellulose acetate membrane with thickness 0.13mm 
soaked in glycerin before use for 2 hr. The permeation depends on nature and type of diffusion cell used. A model receptor 
medium for an in-vitro permeability experiment should mimic the in-vivo condition [14]. 
2.3.4.1Sampling 
The best method of sampling depends on term of time interval, frequency and volume. Sampling was done (0.5 
and 1hr), sample (0.5ml) was drawn and same was replaced in receptor media for in-vitro permeation experiments by using 
Franz diffusion cell [15]. The cellulose acetate synthetic membrane and skin was mounting on the receptor compartment as 
a permeation cell (10 ml of pH 6.8 phosphate buffer as receptor medium). The vehicle (1g) containing the test drug was 
taken as a donor compartment and covered with a paraffin paper. The receptor segment of cell is maintained (37°C) and 
mixed by a magnetic stirrer (600rpm). At predetermined time intervals, aliquots (1ml) of the receptor medium were 
withdrawn and immediately replaced by an equivalent volume of fresh receptor solution and analyzed by UV-method [16]. 
2.3.5Release Kinetics 
To find out the mechanism of drug release from the matrix, the release rate was fitted to equations(Zero-order 
equation: Q=Q0-k0t, where Q is the quantity of drug release at time t, and k0 is the release rate; First-order equation: Q=ln 
Q0-k1t,where k1 is the release rate constant; Higuchi’s equation: Q= k2t
1/2
, where Q = amount of drug release at time (t); k2= 
diffusion rate constant and Korsmeyer Peppas model: Mt/M∞ = Ktn, Where Mt / M∞ is a fraction of drug released at 
time(t); k = release rate constant & n =release exponent). 
2.3.6Irritation Studies 
 
 The Wistar Rats (18 animals approved from the Institutional Animal Ethical Committee (IAEC), Protocol No. 
PDM/CPCSEA/RES/2013/1/1) were used &divided into groups (03); group 1 was served as normal, devoid of treatment; 
group 2 (Control was applied with standard irritant i.e. formalin solution) and topical optimized formulation spray onto 
nude skin of animals (Group 3) [17]. The Draize patch test was carried out using rat as animal model, sprayed area of 
shaved skin with tapes occluded and after 24 hr responses were recorded [18]. 
2.3.7Stability Studies 
According to ICHQ1A (R2) guideline [19] stability results should assemble the proposed storage statement for 
labeling (if applicable), which should be based on the stability estimation of the API [20]. The API is considered as stable if 
it is within the defined/ regulatory terms, when stored at (30±2ºC/65±5%RH) as long term stability for 0, 3, 6, 9, 12, 18 and 
24 months; at (40±2 ºC/75± 5% RH) as an accelerated stability for 0, 2, 3 and 6 months. The formulation was prepared, 
filled in final containers and initial testing was done for various parameters. 20 bottles were kept for 2, 3 and 6 months in 
accelerated stability chamber at 40±2 ºC and 75± 5% RH and 50 bottles were kept for 3months, 6months, 9months, 1 year, 
1
1/2 
years, 2years in real time stability chamber at 30±2 ºC and 65±5% RH. The formulation was evaluated for change in 
physical appearance, pH, assay, evaporation time, average rate per actuation, uniformity of delivery dose and cumulative 
drug release. 
 
3. Result and Discussion 
The formulations were selected & optimized [F30 (Fig. B) and F18 for further studies] on based of clarity of 
solution, evaporation rate, spray pattern and tackiness of film formed. 
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The results of FTIR spectrums (Fig. B) exhibited characteristic peaks at 2973cm
-1
 (C-H aliphatic stretching); 
1711cm
-1
 (C=O stretching); 879cm
-1 
(N-H bend) & 1376cm
-1
 for aryl C-N stretch and showed no possibility of chemical 
interaction between the drug and excipients in optimized formulation. The optimized formulation (F30) absorbance (0.695) 
was determined by UV-Spectrophotometer (methanol as a blank at λmax281nm.) and found drug content (calculated by y = 
0.051x-0.093) which complies with British Pharmacopoeia standard. This point concluded that the drug is distributed 
almost homogeneously and there was no loss of drug in formulation. 
 
Fig. B: FT-IR spectra of Optimized Formulation (F30) 
 
3.1Pump Delivery and Shot Weight
 
The pump (200mcl) valve was actuated to fullest extend and container was re-weighted (g). So, specific gravity 
(equals to density of test solution to density of water) of solution was determined to identify the delivered dose per 
actuation (ml). Densities of both solutions were determined (not more than 10% individual weight deviates from average 
weight and deviation found to be less than 6%. The shot weight of all formulations; Max. & Min. value= 0.21ml & 0.20ml 
with value of Mean& Std. Dev. =0.20 &0.004respectively. 
3.2 Evaporation Time & Weight Checking 
The time required for spray film to dry was predicted by spraying the formulation on skin and drying time was 
noted down (F30 has 9±0.59minute, more drying time due to presence of PK-90 and propylene glycol in formulation than 
F18 (6±0.24minute).The test complies if not more than two individual masses deviate by more than 25% from average 
valve and none of deviate by more than 35%. The weight standard deviation was 0.134g often containers (F30) with 
average weight 29.2g as compared to F18 (0.145g with average weight 29.1g). 
3.3 Delivered Dose Uniformity (Content Uniformity)
 
The dose of the drug distributed per actuation of pump was within the range 88.2-103% & optimized formulation 
showed average drug contents per spray of 98.74± 2.1631%. It indicated the amount of the therapeutically active ingredient 
delivered per metered spray from the metered dose containers & found better uniformity in term of content per spray. This 
procedure repeats for 20 containers. The formulation drug content per actuation is within the limit of 75% to 125% (If 2 or 
3 individual content are outside the limit of 75% to 125% but individual content are within the limit of 65% to 135%). 
3.4 Skin Permeation Studies 
The cumulative amount (mcg/cm
2
) of spray release through synthetic membrane was plotted against time & found 
approx. linear graph. The release profile of optimized formulation demonstrated that the drug permeates cumulative is 
93.3±3.1% in 7hr as compare to marketed formulation 67.9±2.0%cumulativerelease (Fig. C). It showed optimized 
formulation had significantly higher release of drug because of presence of lecithin, film forming agents and permeation 
enhancer.  
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Fig. C: (a) FormulationF18 (EPIC) and formulation F30 (EIPLCP) (b) Comparative release of i.e. F18, F30 and 
Market spray formulation 
 
    (a)                                                                                               (b) 
3.5Release Kinetics 
To know the drug release kinetics of optimized formulation zero order (R
2
=0.9574), first order (R
2
=0.9588), 
Higuchi (R
2
=0.9713), Peppas plot (R
2
=0.9847) were constructed & found in-vitro release profiles of drug from optimized 
formulations (F30) could be greatest expressed by Peppas plot as the plots showed high linearity (R
2
: 0.9847). To verify the 
diffusion mechanism, the data were fitted into Higuchi equation and Korsmeyer-Peppas equation (Fig. D). The results 
demonstrated that the drug formulation (F30) has good linearity (0.9847) with slope values (n) >0.89 to super case II 
transport follows Peppas model. 
       
                   (a)            (b) 
        
(c)         (d) 
Fig. D: (a) Zero order; (b) First order; (c) Higuchi; (d) Peppas plot. 
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3.6 Irritation Study
 
The customized primary skin irritation and corrosion score was allocated form 0 to 4 based on the severity of 
erythema/oedema, this scoring approach given of cutaneous toxicity for a topical system. The optimized formulation’s 
irritation on rat was at 0 level scales for erythma/edema as compared to the standard formalin solution (Fig. E). Result, 
showed there was no sensitivity or irritation type of reaction. 
3.7Stability 
The stability is expressed as the shelf-life, wherein the product is expected to remain fit for its proposed purpose if 
stored properly in its stopped container. Generally shelf-life is defined as the time for the original potency of active drug to 
be reduced to 90%. The shelf life of non-pressurized spray (Fig. F) was found 18 months. The results (Table B and Table C) 
showed stability of formulation was under the acceptance criterion (acceptance condition for the assay alteration with-in5% 
from its initial value) and appearance of spray product remains same. Test performed as per protocol of BP. Based on the 
stability data shelf–life of 18months can be assigned to the product when stored at a temperature of 25oC. 
Table B: Stability Study Results at Accelerated Stability Condition. 
Time 
Intervals 
 
Parameters Study at Temperature 40±2ºC/75±5%RH 
Description Colour 
pH 
(6 to 
7.5) 
Evaporation  
rate 
Assay:-Each ml contains : 
Diclofenac Diethylamine 
BP 4.64 mg  (Limit: NLT 
4.408 mg to 4.872 mg) 
Content 
Uniformity :- 
(Limit: NLT 
75 % to 
125%) 
Cumulative 
drug release 
Initial 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.01 9 minute 4.562mg 97.5±2.02% 93.3±3.10% 
2 
Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.02 9 minute 4.533mg 97.2±3.19% 92.61±3.90% 
3 
Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.03 8 minute 4.519mg 96.4±1.03% 91.8±3.14% 
6 
Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.05 8 minute 4.482mg 96.1± 2.72% 89.8±3.50% 
 
Table C: Stability Study Results at Real Time Stability Condition. 
Time 
Intervals 
 
Parameters Study at Temperature 30±2ºC/65±5%RH 
Description Colour 
pH 
(6 to 
7.5) 
Evaporati
on  rate 
Assay:-Each ml contains 
: Diclofenac 
Diethylamine BP 4.64 mg  
(Limit: NLT 4.408 mg to 
4.872 mg) 
Content Uniformity 
:- (Limit: NLT 75 % 
to 125%) 
Cumulative 
drug release 
Initial 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.01 9 minute 4.562mg 97.5±2.02% 93.3±3.10% 
3 Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.01 9 minute 4.541mg 97.4±3.19% 91.85±2.20% 
6 Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.02 8 minute 4.529mg 97.4±1.93% 90.9±4.60% 
9 Months 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.02 8 minute 4.497mg 96.3± 2.12% 89.4±3.79% 
1 Year 
Clear pale yellow 
liquid free from 
foreign particles. 
Pale 
yellow 
6.03 8 minute 4.483mg 96.1±3.79% 87.9±2.57% 
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4. Conclusion 
The non-pressurized topical spray of Diclofenac Diethylamine was formulated stable and pharmaceutically 
suitable liquid spray. Additionally, this study also emphasized the significance of carefully choosing specific 
pharmaceutical excipients and their most proper concentration in development of non-pressurized topical spray drug 
delivery system. The results were revealed physicochemical stable, non-irritant and non-pressurized topical spray that could 
deliver a considerable of formulation quantity across the skin. It was found that the compositions of topical spray F30 (Fig. 
F); non-occlusive films are perfectly appropriate for spraying application by means of a pump spray container. 
 
 
Fig. E: Rat skin irritation study; (a) Rat skin without any treatment; (b) Rat skin  with treated standard irritant solution of 
formalin showing erythma; (c) Optimized topical spray applied on rat skin; (d) Rat skin after 24hr of application of 
optimized formulation. 
 
Fig. F: Formulation batch (F30) for stability study in HDPE bottle. 
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